- Home
- ENVX vs MNKD Comparison
ENVX vs MNKD Comparison
Compare ENVX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVX
- MNKD
- Stock Information
- Founded
- ENVX 2006
- MNKD 1991
- Country
- ENVX United States
- MNKD United States
- Employees
- ENVX N/A
- MNKD N/A
- Industry
- ENVX Industrial Machinery/Components
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- ENVX Miscellaneous
- MNKD Health Care
- Exchange
- ENVX Nasdaq
- MNKD Nasdaq
- Market Cap
- ENVX 1.6B
- MNKD 1.8B
- IPO Year
- ENVX N/A
- MNKD 2004
- Fundamental
- Price
- ENVX $11.43
- MNKD $6.60
- Analyst Decision
- ENVX Strong Buy
- MNKD Strong Buy
- Analyst Count
- ENVX 10
- MNKD 6
- Target Price
- ENVX $21.60
- MNKD $8.67
- AVG Volume (30 Days)
- ENVX 5.7M
- MNKD 1.8M
- Earning Date
- ENVX 11-05-2024
- MNKD 11-05-2024
- Dividend Yield
- ENVX N/A
- MNKD N/A
- EPS Growth
- ENVX N/A
- MNKD N/A
- EPS
- ENVX N/A
- MNKD 0.04
- Revenue
- ENVX $16,620,999.00
- MNKD $248,374,000.00
- Revenue This Year
- ENVX $175.94
- MNKD $48.01
- Revenue Next Year
- ENVX $158.55
- MNKD $14.08
- P/E Ratio
- ENVX N/A
- MNKD $152.19
- Revenue Growth
- ENVX 1327.92
- MNKD 57.08
- 52 Week Low
- ENVX $5.70
- MNKD $3.17
- 52 Week High
- ENVX $18.68
- MNKD $6.92
- Technical
- Relative Strength Index (RSI)
- ENVX 54.33
- MNKD 59.23
- Support Level
- ENVX $10.51
- MNKD $6.25
- Resistance Level
- ENVX $13.19
- MNKD $6.56
- Average True Range (ATR)
- ENVX 1.03
- MNKD 0.20
- MACD
- ENVX 0.09
- MNKD 0.00
- Stochastic Oscillator
- ENVX 62.47
- MNKD 69.70
About ENVX Enovix Corporation
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.